Search

Your search keyword '"Hoogendoorn, Mels"' showing total 32 results
Start Over Author "Hoogendoorn, Mels" Publisher american society of hematology
32 results on '"Hoogendoorn, Mels"'

1. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Author

van der Straten, Lina, primary, Stege, Claudia A. M., additional, Kersting, Sabina, additional, Nasserinejad, Kazem, additional, Dubois, Julie, additional, Dobber, Johan A., additional, Mellink, Clemens H. M., additional, van der Kevie-Kersemaekers, Anne-Marie F., additional, Evers, Ludo M., additional, de Boer, Fransien, additional, Koene, Harry R., additional, Schreurs, John, additional, van der Klift, Marjolein, additional, Velders, Gerjo A., additional, van der Spek, Ellen, additional, van der Straaten, Hanneke M., additional, Hoogendoorn, Mels, additional, van Gelder, Michel, additional, Posthuma, Eduardus F. M., additional, Visser, Hein P. J., additional, Houtenbos, Ilse, additional, Idink, Cecile A. M., additional, Issa, Djamila E., additional, Dompeling, Ellen C., additional, van Zaanen, Henk C. T., additional, Veelken, J. Hendrik, additional, Levenga, Henriette, additional, Tick, Lidwine W., additional, Terpstra, Wim E., additional, Tonino, Sanne H., additional, Westerweel, Peter E., additional, Langerak, Anton W., additional, Kater, Arnon P., additional, and Levin, Mark-David, additional

Published
2023
Full Text
View/download PDF

2. Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population

Author

Kockerols, Camille C.B., primary, Valk, Peter JM, additional, Blijlevens, Nicole M A, additional, Cornelissen, Jan J., additional, Dinmohamed, Avinash G., additional, Geelen, Inge, additional, Hoogendoorn, Mels, additional, Janssen, Jeroen J.W.M., additional, Daenen, Laura G.M., additional, van der Reijden, Bert A., additional, and Westerweel, Peter E., additional

Published
2022
Full Text
View/download PDF

4. A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Author

Eichhorst, Barbara, primary, Niemann, Carsten, additional, Kater, Arnon P., additional, Fürstenau, Moritz, additional, Von Tresckow, Julia, additional, Zhang, Can, additional, Robrecht, Sandra, additional, Gregor, Michael, additional, Juliusson, Gunnar, additional, Thornton, Patrick, additional, Staber, Philipp B., additional, Tadmor, Tamar, additional, Lindström, Vesa, additional, Da Cunha-Bang, Caspar, additional, Schneider, Christof, additional, Poulsen, Christian Bjørn, additional, Illmer, Thomas, additional, Schöttker, Björn, additional, Janssens, Ann, additional, Christiansen, Ilse, additional, Noesslinger, Thomas, additional, Baumann, Michael, additional, van der Klift, Marjolein, additional, Jaeger, Ulrich, additional, Frederiksen, Henrik, additional, Leijs, Maria B.L., additional, Hoogendoorn, Mels, additional, Lotfi, Kourosh, additional, Hebart, Holger, additional, Gaska, Tobias, additional, Koene, Harry R., additional, Simon, Florian, additional, De Silva, Nisha, additional, Fink, Anna-Maria, additional, Fischer, Kirsten, additional, Wendtner, Clemens-Martin, additional, Kreuzer, Karl-Anton, additional, Ritgen, Matthias, additional, Brüggemann, Monika, additional, Tausch, Eugen, additional, Levin, Mark-David, additional, Van Oers, Marinus H.J., additional, Geisler, Christian H., additional, Stilgenbauer, Stephan, additional, and Hallek, Michael, additional

Published
2021
Full Text
View/download PDF

7. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, primary, Pabst, Thomas, additional, Maertens, Johan, additional, Gradowska, Patrycja, additional, Biemond, Bart J., additional, Spertini, Olivier, additional, Vellenga, Edo, additional, Griskevicius, Laimonas, additional, Tick, Lidwine W., additional, Jongen-Lavrencic, Mojca, additional, van Marwijk Kooy, Marinus, additional, Vekemans, Marie-Christiane, additional, van der Velden, Walter J. F. M., additional, Beverloo, Berna, additional, Michaux, Lucienne, additional, Graux, Carlos, additional, Deeren, Dries, additional, de Weerdt, Okke, additional, van Esser, Joost W. J., additional, Bargetzi, Mario, additional, Klein, Saskia K., additional, Gadisseur, Alain, additional, Westerweel, Peter E., additional, Veelken, Hendrik, additional, Gregor, Michael, additional, Silzle, Tobias, additional, van Lammeren-Venema, Daniëlle, additional, Moors, Ine, additional, Breems, Dimitri A., additional, Hoogendoorn, Mels, additional, Legdeur, Marie-Cecile J. C., additional, Fischer, Thomas, additional, Kuball, Juergen, additional, Cornelissen, Jan, additional, Porkka, Kimmo, additional, Juliusson, Gunnar, additional, Meyer, Peter, additional, Höglund, Martin, additional, Gjertsen, Bjorn T., additional, Janssen, Jeroen J. W. M., additional, Huls, Gerwin, additional, Passweg, Jakob, additional, Cloos, Jacqueline, additional, Valk, Peter J. M., additional, van Elssen, Catharina H. M. J., additional, Manz, Markus G., additional, Floisand, Yngvar, additional, and Ossenkoppele, Gert J., additional

Published
2021
Full Text
View/download PDF

8. Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Author

Huls, Gerwin, primary, Chitu, Dana A., additional, Pabst, Thomas, additional, Klein, Saskia K., additional, Stussi, Georg, additional, Griskevicius, Laimonas, additional, Valk, Peter J. M., additional, Cloos, Jacqueline, additional, van de Loosdrecht, Arjan A., additional, Breems, Dimitri, additional, van Lammeren-Venema, Danielle, additional, van Zeventer, Isabelle, additional, Boersma, Rinske, additional, Jongen-Lavrencic, Mojca, additional, Fehr, Martin, additional, Hoogendoorn, Mels, additional, Manz, Markus G., additional, Söhne, Maaike, additional, van Marwijk Kooy, Rien, additional, Deeren, Dries, additional, van der Poel, Marjolein W. M., additional, Legdeur, Marie Cecile, additional, Tick, Lidwine, additional, Chalandon, Yves, additional, Ammatuna, Emanuele, additional, Blum, Sabine, additional, Löwenberg, Bob, additional, and Ossenkoppele, Gert J., additional

Published
2020
Full Text
View/download PDF

12. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Author

de Weerdt, Iris, primary, Hofland, Tom, primary, de Boer, Renate, primary, Dobber, Johan A., primary, Dubois, Julie, primary, van Nieuwenhuize, Denise, primary, Mobasher, Mehrdad, primary, de Boer, Fransien, primary, Hoogendoorn, Mels, primary, Velders, Gerjo A., primary, van der Klift, Marjolein, primary, Remmerswaal, Ester B. M., primary, Bemelman, Frederike J., primary, Niemann, Carsten U., primary, Kersting, Sabina, primary, Levin, Mark-David, primary, Eldering, Eric, primary, Tonino, Sanne H., primary, and Kater, Arnon P., primary

Published
2019
Full Text
View/download PDF

13. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Author

Kater, Arnon P., primary, Kersting, Sabina, additional, van Norden, Yvette, additional, Dubois, Julie, additional, Dobber, Johan A., additional, Mellink, Clemens H., additional, Evers, Ludo M., additional, Croon-de Boer, Fransien, additional, Schreurs, John, additional, van der Spek, Ellen, additional, Visser, Hein, additional, Idink, Cecile, additional, Wittebol, Shulamiet, additional, Hoogendoorn, Mels, additional, Tonino, Sanne H., additional, Mobasher, Mehrdad, additional, and Levin, Mark-David, additional

Published
2018
Full Text
View/download PDF

14. First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment

Author

de Weerdt, Iris, primary, Hofland, Tom, additional, Dobber, Johan, additional, Dubois, Julie, additional, Eldering, Eric, additional, Mobasher, Mehrdad, additional, Croon-de Boer, Fransien, additional, Hoogendoorn, Mels, additional, Velders, Gerjo A., additional, van der Klift, Marjolein, additional, Levin, Mark-David, additional, Kersting, Sabina, additional, Tonino, Sanne, additional, and Kater, Arnon P., additional

Published
2018
Full Text
View/download PDF

15. Rituximab-Pecc Induction Followed By 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Author

Lugtenburg, Pieternella J, primary, Zijlstra, Josée M, additional, Doorduijn, Jeanette K, additional, Böhmer, Lara H, additional, van Marwijk Kooy, Marinus, additional, Hoogendoorn, Mels, additional, Berenschot, Henriette W, additional, Beeker, Aart, additional, Valster, Fransje, additional, Schouten, Harry C., additional, Luten, Marleen, additional, Hofwegen, Henk, additional, Chitu, Dana A, additional, Brouwer, Rolf E, additional, and van Imhoff, Gustaaf W, additional

Published
2015
Full Text
View/download PDF

16. Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

Author

te Raa, Doreen, primary, Moerland, Perry, additional, Leeksma, Alexander, additional, Derks, Ingrid, additional, Loden, Martin, additional, Navrkalova, Veronika, additional, Trbusek, Martin, additional, Luijks, Dieuwertje, additional, Zenz, Thorsten, additional, Skowronska, Anna, additional, Stankovic, Tatjana, additional, Hoogendoorn, Mels, additional, van Oers, Marinus H. J., additional, Eldering, Eric, additional, and Kater, Arnon P., additional

Published
2015
Full Text
View/download PDF

18. Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study

Author

Waal de, Esther GM, primary, Munck de, Linda, additional, Woolthuis, Gerhard, additional, velden Van Der, Annet, additional, Tromp, Yvonne, additional, Hoogendoorn, Mels, additional, Vellenga, Edo, additional, and Hovenga, Sjoerd, additional

Published
2014
Full Text
View/download PDF

19. Overall Survival Patterns in Patients with Multiple Myeloma in the Era of Novel Agents and the Role of Initial Clinical Presentation and Comorbidities: A Population-Based Study

Author

Oortgiesen, Berdien, primary, Roon, Eric N. van, additional, Joosten, Peter, additional, Kibbelaar, Robby, additional, Storm, Huib, additional, Hovenga, Sjoerd, additional, Van Rees, Bas P, additional, Woolthuis, Gerhard, additional, Veeger, Nic J.G.M., additional, and Hoogendoorn, Mels, additional

Published
2014
Full Text
View/download PDF

20. R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Author

Van Gelder, Michel, primary, Ghidey, Wendim, additional, Chamuleau, Martine ED, additional, Cornelissen, Jan, additional, Petersen, Eefke J, additional, Daenen, Simon M. G. J., additional, Zachee, Pierre, additional, Hoogendoorn, Mels, additional, Beker, Aart, additional, Timmers, Gert Jan, additional, Kater, Arnon P., additional, and Van Oers, Marinus H.J., additional

Published
2013
Full Text
View/download PDF

21. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

Author

Ossenkoppele, Gert J., primary, Stussi, Georg, additional, Maertens, Johan, additional, van Montfort, Kees, additional, Biemond, Bart J., additional, Breems, Dimitri, additional, Ferrant, August, additional, Graux, Carlos, additional, de Greef, Georgine E., additional, Halkes, C. J. M., additional, Hoogendoorn, Mels, additional, Hollestein, Rene M., additional, Jongen-Lavrencic, Mojca, additional, Levin, Mark D., additional, van de Loosdrecht, Arjan A., additional, van Marwijk Kooij, Marinus, additional, van Norden, Yvette, additional, Pabst, Thomas, additional, Schouten, Harry C., additional, Vellenga, Edo, additional, Verhoef, Gregor E. G., additional, de Weerdt, Okke, additional, Wijermans, Pierre, additional, Passweg, Jakob R., additional, and Löwenberg, Bob, additional

Published
2012
Full Text
View/download PDF

22. Rituximab-PECC Induction Followed by 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Author

Lugtenburg, Pieternella J, primary, Zijlstra, Josée M, additional, Doorduijn, Jeanette K, additional, Böhmer, Lara H, additional, van Marwijk Kooy, Marinus, additional, Hoogendoorn, Mels, additional, Berenschot, Henriette W, additional, Beeker, Aart, additional, Valster, Fransje A, additional, Schouten, Harry C, additional, Luten, Marleen, additional, Chitu, Dana A, additional, Brouwer, Rolf E, additional, and van Imhoff, Gustaaf W, additional

Published
2012
Full Text
View/download PDF

25. A Significant Better Two Year Survival in the Very Elderly Patients with a Diffuse Large B-Cell Lymphoma (DLBCL) Who Did Complete Standard Therapy: A Population-Based Cohort Study On Treatment, Toxicity and Outcome.

Author

Boslooper, Karin, primary, Joosten, Peter, additional, Veeger, Nic J.G.M., additional, Kibbelaar, Robby, additional, van Roon, Eric, additional, Hovenga, Sjoerd, additional, Woolthuis, Gerhard, additional, Kluin-Nelemans, Hanneke C., additional, and Hoogendoorn, Mels, additional

Published
2012
Full Text
View/download PDF

26. R-DHAP Immuno-Chemotherapy Is An Effective Remission-Induction Treatment for Fludarabine Refractory CLL Patients and Allows the Majority to Proceed to Allogeneic Stem Cell Transplantation. Results of the Planned Interim Analysis of the Dutch-Belgian Prospective Multicenter HOVON88 Trial,

Author

Van Gelder, Michel, primary, Ghidey, Wendim, additional, Chamuleau, Martine ED, additional, Cornelissen, Jan J, additional, Wu, Ka Lung, additional, Hoogendoorn, Mels, additional, Daenen, S. M. G. J., additional, Petersen, Eefke, additional, and van Oers, Marinus H. J., additional

Published
2011
Full Text
View/download PDF

27. Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Author

Huls, Geert A, primary, van der Helm, Lieke H., additional, Alhan, Canan, additional, Wijermans, P.W., additional, van Marwijk Kooy, Marinus, additional, Schaafsma, Martijn R., additional, Biemond, Bart J, additional, Beeker, Aart, additional, Hoogendoorn, Mels, additional, van Rees, Bastiaan P., additional, de Weerdt, Okke, additional, Wegman, Jurgen, additional, Libourel, Eduard J, additional, Luykx-de Bakker, Sylvia A., additional, Minnema, Monique C., additional, Brouwer, Rolf, additional, Croon-de Boer, Fransien, additional, Eefting, Matthias, additional, Jie, Kon-Siong G., additional, van der Loosdrecht, Arjan A., additional, Koedam, Jan, additional, Veeger, Nic J.G.M., additional, and Vellenga, Edo, additional

Published
2011
Full Text
View/download PDF

31. A Two Step Nonmyeloablative Allogeneic Transplantation Protocol Using In Vitro T-Cell Depleted Mobilized Stem Cells Followed by Donor Lymphocyte Infusions in Patients with Advanced CLL.

Author

Barge, Renee M.Y., primary, Hoogendoorn, Mels, primary, Marijt, Erik W.A., primary, Beaumont, Floor, primary, Starrenburg, Ingrid, primary, Smit, Willem, primary, Posthuma, Ward, primary, Fibbe, Willem E., primary, Falkenburg, Frederik, primary, and Willemze, Roelof, primary

Published
2005
Full Text
View/download PDF

32. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J, Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W, Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J F M, Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W J, Bargetzi, Mario, Klein, Saskia K, Gadisseur, Alain, Westerweel, Peter E, Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A, Hoogendoorn, Mels, Legdeur, Marie-Cecile J C, Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T, Janssen, Jeroen J W M, Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J M, van Elssen, Catharina H M J, Manz, Markus G, Floisand, Yngvar, and Ossenkoppele, Gert J

Subjects
hemic and lymphatic diseases, 610 Medizin und Gesundheit, 3. Good health
Abstract

Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and intermediate-dose cytarabine (cycle 2) without or with lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy or autologous stem cell transplantation (auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and minimal residual disease (MRD)-adapted approach. Event-free survival (EFS; primary end point) and other clinical end points were assessed. A second random assignment in patients in complete response or in complete response with incomplete hematologic recovery after cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21) or observation. In all, 392 patients were randomly assigned to the control group, and 388 patients were randomly assigned to lenalidomide induction. At a median follow-up of 41 months, the study revealed no differences in outcome between the treatments (EFS, 44% ± 2% standard error and overall survival, 54% ± 2% at 4 years for both arms) although in an exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML. In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen but did not pursue an MRD-guided approach, these survival estimates compare markedly more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study.

Catalog

Books, media, physical & digital resources
See catalog results